

## Identification a lead small-molecule drug to treat osteoarthritis through a cartilage regeneration mechanism

KaiPharm Co., Ltd.



IMMUNOLOGY	Hit
Product Type	Small molecule
Indication	Osteoarthritis
Target	OSCAR
MoA(Mechanism of Action)	Inhibition of chondrocyte apoptosis
Competitiveness	<ol style="list-style-type: none"> <li>1. EK molecules (EKs) are first-in-class candidates inhibiting OSCAR (osteoclast-associated receptor) for osteoarthritis treatment.</li> <li>2. Small-molecule drugs can be administered by multiple routes, including orally. Thus, we now inject EKs intra-articular, but there is still a chance to improve properties in development process and expand patent rights.</li> <li>3. EKs significantly enhance cartilage regeneration in-house mouse experiments, demonstrating a potential as DMOADs (disease-modifying osteoarthritis drugs).</li> </ol>
Development Stage	Hit
Route of Administration	IAI (Intra Articular Injection)